We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Leslie Castelo-Soccio MD, PhD

Leslie Castelo-Soccio MD, PhD

Pediatric Dermatologist, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland

Leslie Castelo-Soccio, MD, PhD, received her undergraduate degree from Harvard University and her medical and doctoral degrees from the Tri-Institutional MD-PhD program at Cornell University. After training in dermatology at the University of Pennsylvania, she completed a pediatric dermatology fellowship at the Children's Hospital of Philadelphia and a post-doctoral fellowship in the hair and pigment disorders at the University of Pennsylvania.

From 2011-2021, Dr. Castelo-Soccio was an assistant professor of pediatrics and dermatology at the University of Pennsylvania Perelman School of Medicine and the research director and an attending physician in pediatric dermatology at the Children's Hospital of Philadelphia.

In 2021, she joined the National Institute for Arthritis and Musculoskeletal and Skin diseases at the National Institutes of Health as a staff clinician and research physician. Dr. Castelo-Soccio's research covers the natural history of alopecia including epidemiology, associated co-morbidities, and response to therapy. She specializes in imaging tools and guidelines for pediatric alopecia.

Dr. Castelo-Soccio also studies the microbiome of skin disorders with the goal of developing therapies targeting dysbiosis and immune system dysregulation.


Dr. Castelo-Soccio previously was a principal investigator for Amryt Pharmaceuticals for the Oleogel EB study (relationship has ended). In the past, she received honoraria and grants from Pfizer (relationship has ended).

Dr. Castelo-Soccio currently has no relevant disclosures.